The preliminary data released by the Centers for Disease Control and Prevention (CDC) at the National STD Prevention Conference in Washington, D.C have found that almost 2.3 million cases about gonorrhoea, syphilis and Chlamydia had been diagnosed in the United States in the year 2017.This has surpassed an earlier record that was set in 2016 by not less than 200,000 cases. This actually marked the fourth consecutive year of a rise in sexually transmitted diseases or STDs.
Gonorrhoea diagnoses have increased by 67 percent on the whole and almost double among men which is from 169,130 to 322,169. There has also been an increase in diagnoses among women and the speed at which it is increasing is a matter of concern with cases increasing from 197,499 to 232,587 in the third year.
Primary and secondary syphilis diagnoses have increased by 76 percent from 17,375 to 30,644 cases. Bisexual, gay and other men enjoying sex with men (MSM) seem to have made up near about 70 percent of primary and secondary syphilis cases. Here, the gender of sex partner is usually known by 2017. Primary and secondary syphilis seem to be the most infectious stages of this particular disease.
Chlamydia has been the most common condition reported to CDC. Almost 1.7 million cases were been diagnosed in the year 2017 having 45 percent among 15- to 24-year-old females.
According to Jonathan Mermin, M.D., M.P.H, director of CDC’s National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, “We are sliding backwards.” “It is evident the systems that identify, treat, and ultimately prevent STDs are strained to near-breaking point.”
Chlamydia, syphilis and gonorrhoea can be treated by taking antibiotics, yet most of them might go undiagnosed as well as untreated. This, in turn, may cause severe health effects such as ectopic pregnancy, infertility, increased HIV risks and stillbirth in infants. Studies have found that there are various factors that contribute to the increase in STDs include socio-economic factors such as poverty, discrimination, drug use and stigma.
Continued concerns for antibiotic-resistant gonorrhoea:
The risks for a non-curable gonorrhoea are still there in the United States and the reports have only supported the concerns. Gonorrhoea has now become resistant for almost all classes of antibiotics to treat it. However, ceftriaxone is the only effective antibiotic that helps in the treatment ofgonorrhoea in the United States.
In the year 2015, CDC has suggested thathealth care providers to prescribe ceftriaxone that is often accompanied by an oral dose of azithromycin to people for treatinggonorrhoea. Azithromycin was also added to delay the growth of resistance to ceftriaxone.
According to the new CDC findings, emerging resistance to azithromycin has been on the rise in the laboratory testing. However, the portion of samples that has shown emerging resistance to azithromycin increased from 1 percent in 2013 to not less than 4 percent in the year 2017.
Azithromycin-resistant genes mightintersect into the strains of gonorrhoea with lessened susceptibility to ceftriaxone in some gonorrhoea. Also, the strain of gonorrhoea may surface someday that fail to give any response to ceftriaxone.
Gail Bolan, M.D., director of CDC’s Division of STD Prevention has said, “We expect gonorrhoea will eventually wear down our last highly effective antibiotic, and additional treatment options are urgently needed.” “We can’t let our defences down — we must continue reinforcing efforts to rapidly detect and prevent resistance as long as possible.”
There has been anew commitment from the healthcare providers who prepare STD screening and timely treatment as a normal part of medical care. This is particularly for the people who have been most affected and are an important component to reverse present trends.
Top 6 Health Threats that Men need to be Aware About07 May, 2019
Cancer – Diagnosis and Treatment09 Apr, 2019